Small chance of vaccine by Christmas says head of Oxford/AstraZeneca trial

Share

The minister highlighted that the results of studies of the first and second phases of clinical trials proved that the vaccine is safe and effective, adding that the trials are conducted under the strict supervision of the medical teams and the Ministry of Health.

"I'm optimistic that we could reach that point before the end of this year", Oxford Vaccine Trial Chief Investigator Andrew Pollard told British lawmakers of presenting trial results this year.

Novavax?is now conducting multiple clinical trials for NVX-CoV2373, its vaccine candidate against the virus that causes COVID-19, including a pivotal Phase 3 clinical trial in the United Kingdom to evaluate the efficacy, safety and immunogenicity in individuals aged 18-84 years of age.

Overall, there are more than 200 candidate vaccines in development worldwide, with 44 in clinical trials.

Europe's drug regulator will not set a minimum level of efficacy for potential COVID-19 vaccines when considering them for approval, it said on Wednesday, taking a different approach to that of its US counterpart.

"Difficult to say if vaccine could be deployed before Christmas".

G42 Healthcare CEO Ashish Koshy last month said the vaccine had been administered to more than 31,000 people across those countries.

After that, the vaccine candidates will need regulatory approval, Bingham said.

Covid-19: PM says 'Now is the time to take action'
Johnson's government, which is responsible for health policy in England only, had resisted the move, fearing the economic fallout. People walk past a poster by artist Hayden Kay criticizing the Conservative government's pandemic response in London on Saturday.

"The findings indicate that COVID-19 is not simply a disease caused by the death of virus-infected cells, but is likely the outcome of these abnormal cells persisting for long periods inside the lungs", said Mauro Giacca, a professor at King's College London who co-led the work.

It follows warnings from government scientists the NHS will be overwhelmed with thousands more deaths unless action is taken.

Sir Simon Stevens said a potential vaccination programme will see vaccines delivered at GP surgeries, pharmacies and mass testing centres - including at the Nightingale hospitals.

He added that the health service "is adding as much capacity as possible" in anticipation of the usual winter pressures and Covid patients. "They're giving with one hand and taking with the other", Taylor said.

Germany has asked the Robert Koch Institute's vaccine committee to identify which vulnerable population groups should get the shots first, although front-line workers are expected to be a priority.

The planned global Phase 3 clinical programs evaluating NVX-CoV2373 will assess immunity, safety and COVID-19 disease prevention.

It comes as the head of the UK's vaccines taskforce said that data from the vaccine trials at the University of Oxford and AstraZeneca and Pfizer with BioNTech could be available this year.

"Once approved, the NHS is ready to begin vaccination activities among the more at-risk, before launching more".

Share